Enzalutamide After Docetaxel and Abiraterone Therapy in Metastatic Castration-Resistant Prostate Cancer

Overview of attention for article published in Advances in Therapy, January 2014

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Average Attention Score compared to outputs of the same age and source

Mentioned by

policy: 1 policy source

Citations

dimensions_citation: 57 Dimensions

Readers on

mendeley: 56 Mendeley

Summary Policy documents Dimensions citations

So far, Altmetric has seen 2 policy documents that reference this research output.

Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel: Committee papers

Cited by National Institute for Health and Care Excellence on 01 Feb 2016

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen: Prostate cancer (hormone relapsed, metastatic) - enzalutamide (after docetaxel): evaluation report

Cited by National Institute for Health and Care Excellence on 09 May 2014

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.